The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Blinatumomab + ponatinib in patients with newly diagnosed Ph+ ALL: Phase II findings
|
Blinatumomab + ponatinib has the potential to offer a chemotherapy-free regimen in patients with Ph+ ALL. Results from a phase II trial evaluating the efficacy and safety of the combination in 76 patients with ND Ph+ ALL were presented by Nicholas Short at the 66th ASH Annual Meeting and Exposition.1 |
| Key learnings |
|
Blinatumomab + ponatinib produced a CR/CRi rate in 98% of patients, a CMR-negative status in 83%, and a NGS MRD-negative status in 96%. |
| At a median follow-up of 29 months, the 3-year RFS and OS were 78% and 88%, respectively. MVA showed that WBC ≥70,000 vs ≤70,000 was associated with relapse, with a CIR of 52% vs 6% (p < 0.001). |
| Relapse and death in patients with a CR were reported in 13.2% and 4.0% of patients, respectively, while 3.0% of patients received transplantation. |
| The results show that the blinatumomab + ponatinib achieved deep and durable responses in patients with ND Ph+ ALL. However, novel strategies are needed for patients with high-risk Ph+ ALL. |
Abbreviations: ALL, acute lymphoblastic leukemia; CIR, cumulative incidence of relapse; CMR, complete molecular remission; CR, complete remission; CRi, CR with incomplete hematologic recovery; MVA, multivariate analysis; ND, newly diagnosed; NGS, next-generation sequencing; MRD, measurable residual disease; OS, overall survival; Ph+, Philadelphia chromosome-positive; RFS, relapse-free survival; WBC, white blood cell.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
